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Abstract A human Cu,Zn-superoxide dismutase (Cu,Zn-SOD)
gene was fused with a gene fragment encoding the nine amino
acid transactivator of transcription (Tat) protein transduction
domain (RKKRRQRRR) of HIV-1 in a bacterial expression
vector to produce a genetic in-frame Tat^SOD fusion protein.
The expressed and purified Tat^SOD fusion protein in
Escherichia coli can enter HeLa cells in a time- and dose-
dependent manner when added exogenously in a culture media.
Denatured Tat^SOD protein was transduced much more
efficiently into cells than were native proteins. Once inside the
cells, transduced Tat^SOD protein was enzymatically active and
stable for 24 h. The cell viability of HeLa cells treated with
paraquat, an intracellular superoxide anion generator, was
increased by transduced Tat^SOD. These lines of results suggest
that the transduction of Tat^SOD fusion protein may be one of
the ways to replenish the Cu,Zn-SOD in the various disorders
related to this antioxidant enzyme. ß 2000 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
The reactive-oxygen species are inevitably formed as by-
products of various, normal cellular processes involving inter-
actions with oxygen. These reactive-oxygen species damage
macromolecules in the cells, and therefore, sometimes make
signi¢cant contributions to the several pathological processes
of human diseases, including carcinogenesis, ischemia, radia-
tion injury, and in£ammation/immune injury [1,2]. Cu,Zn-
superoxide dismutase (Cu,Zn-SOD) is among the key cellular
enzymes by which cells detoxify free radicals and protect
themselves from oxidative damage [3].
Since every biological macromolecule can serve as a target
for the damaging action of the abundant oxygen radicals,
interest has grown over the therapeutic potential of SOD.
There has been considerable interest in the use of SOD be-
cause of its role in protection against human diseases. A wide
variety of Cu,Zn-SOD, conjugated or encapsulated, are avail-
able, including SOD conjugated with polyethylene glycol, Fi-
coll, lecithin, albumin, and SOD encapsulated with liposome
[2,4^6]. All of the above have longer circulating half-lives than
the untreated SOD molecules. In addition, gene therapy and
transgenesis have been suggested as a clinical delivery system
of SOD [7^9]. Currently, gene therapy has been widely ex-
ploited, and it is considered a promising method to introduce
therapeutic proteins into the cells. However, this technique
may have some constraints, including gene delivery, pro-
longed gene expression, e⁄cacy, and toxicity [10].
It has been recently reported that the basic domain of hu-
man immunode¢ciency virus type 1 (HIV-1) transactivator of
transcription (Tat) protein possesses the ability to traverse
biological membranes e⁄ciently in a process termed ‘protein
transduction’ [11^14]. Although the mechanism is unknown,
transduction occurs in receptor- and transporter-independent
fashion that appears to target the lipid bilayer directly [14,15].
Furthermore, HIV-1 Tat proteins have recently been shown to
serve as carriers to direct uptake of heterologous proteins,
including ovalbumin, L-galactosidase, and horseradish peroxi-
dase, into the cells in vitro and in vivo [16^18]. Thus, HIV-1
Tat proteins have tremendous potential to deliver large-sized
compounds into the cells.
In the present study, we describe the transduction of full-
length Tat^SOD fusion protein into HeLa cells and whether
this transduced Tat^SOD has a protective e¡ect against oxi-
dative stress in the cells.
2. Materials and methods
2.1. Materials
Restriction endonucleases and T4 DNA ligase were purchased
from Promega Co. Pfu polymerase was obtained from Stratagene.
Oligonucleotides were synthesized from Gibco BRL custom primers.
Isopropyl-L-D-thiogalactoside (IPTG) was obtained from Duchefa
Co. Plasmid pET15b and Escherichia coli strain BL21 (DE3) were
from Novagen. Ni2-nitrilotriacetic acid Sepharose super£ow was
purchased from Qiagen. A human Cu,Zn-SOD cDNA fragment was
isolated using the polymerase chain reaction (PCR) technique from
the VZap human placenta cDNA library [19] and a monoclonal anti-
body raised against human Cu,Zn-SOD was produced in our labora-
tory.
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 0 ) 0 2 2 1 5 - 8
*Corresponding author. Fax: (82)-33-241 1463.
E-mail: sychoi@sun.hallym.ac.kr
Abbreviations: HIV-1, human immunode¢ciency virus type 1; Tat,
transactivator of transcription; Cu,Zn-SOD, Cu,Zn-superoxide dis-
mutase; PCR, polymerase chain reaction; IPTG, isopropyl-L-D-thio-
galactoside; SDS^PAGE, sodium dodecyl sulfate-polyacrylamide gel
electrophoresis; PBS, phosphate-bu¡ered saline
FEBS 24317 17-11-00
FEBS 24317 FEBS Letters 485 (2000) 163^167
2.2. Expression and puri¢cation of Tat^SOD
The pTat^SOD expression vector was constructed to express the
basic domain (amino acids 49^57) of HIV-1 Tat as a fusion with
Cu,Zn-SOD as follows: First, two oligonucleotides were synthesized
and annealed to generate a double-stranded oligonucleotide encoding
nine amino acids from the basic domain of HIV-1 Tat. The sequences
are (top strand) 5P-TAGGAAGAAGCGGAGACAGCGACGAA-
GAC-3P and (bottom strand) 5P-TCGAGTCTTCGTCGCTGTCTC-
CGCTTCTTCC-3P. The double-stranded oligonucleotide was directly
ligated into the NdeI^XhoI-digested pET15b in frame with the six
histidine open-reading frame to generate the HisTat expression plas-
mid, pHisTat. The sequences of the polylinkers cloned into the plas-
mid were con¢rmed with a £uorescence-based automated sequencer
(model 373A; Applied Biosystems, Inc.).
Next, on the basis of the cDNA sequence of human Cu,Zn-SOD,
two oligonucleotides were synthesized. The top strand, 5P-CTC-
GAGGCGACGAAGGCCGTGTGCGTG-3P, contains an XhoI
restriction site, and the bottom strand, 5P-GGATCCTTATTGGGC-
GATCCCAATTAC-3P, contains a BamHI restriction site. The reac-
tion mixture was made up in a 50 Wl siliconized reaction tube and
heated at 94‡C for 5 min. The program for PCR consisted of 30 cycles
of extension at 94‡C for 40 s, denaturation at 54‡C for 1 min, anneal-
ing at 70‡C for 3 min, and the ¢nal extension at 72‡C for 10 min,
20‡C for 5 min.
The PCR products were puri¢ed by preparative agarose gel electro-
phoresis. The puri¢ed products were ligated into a TA-cloning vector
(Invitrogen) and then transformed into a competent cell. The plasmids
of selected colonies were puri¢ed by using an alkaline lysis method
[20]. The puri¢ed TA vector containing human SOD1 cDNA was
digested with XhoI and BamHI, and then subcloned into a pET15b
and pTat expression vector which had been digested with the same
restriction enzymes (Fig. 1). The host E. coli BL21(DE3) was trans-
formed with pSOD and pTat^SOD, and then the transformants were
selected on a LB plate containing ampicillin. The selected colonies
were cultured in a LB medium containing ampicillin at 37‡C with
shaking at 200 rpm. After the cells had grown until OD600 =
0.5V1.0, IPTG was added to a concentration of 0.5 mM, and the
incubation was continued for 3 h. The cells were harvested, and a 5 ml
binding bu¡er (5 mM imidazole, 0.5 M NaCl, 20 mM Tris^HCl, pH
7.9) was added and sonicated. The recombinant Tat^SOD was puri-
¢ed under denaturing and native conditions, respectively. To denature
Tat^SOD, harvested cells were disrupted by sonication in a binding
bu¡er containing 6 M urea. After centrifugation, supernatants con-
taining Tat^SOD were immediately loaded onto a 2.5 ml Ni2-nitri-
lotriacetic acid Sepharose column. After the column was washed with
10 volumes of a binding bu¡er and six volumes of a washing bu¡er
(60 mM imidazole, 0.5 M NaCl, 20 mM Tris^HCl, pH 7.9), the fusion
protein was eluted with an elution bu¡er (1 M imidazole, 0.5 M NaCl,
20 mM Tris^HCl, pH 7.9). The fusion protein containing fractions
were combined and the salts were removed using Sephadex G-15
column chromatography. The protein concentration in fractions was
estimated by the Bradford procedure using bovine serum albumin as a
standard [21].
2.3. Transduction of Tat^SOD into cultured HeLa cells
The HeLa cells were cultured in Dulbecco’s modi¢ed Eagle’s me-
dium containing 20 mM HEPES/NaOH (pH 7.4), 5 mM NaHCO3,
10% fetal bovine serum, and antibiotics (100 Wg/ml streptomycin, 100
U/ml penicillin) at 37‡C under a humidi¢ed condition of 95% air and
5% CO2. For the transduction of Tat^SOD, HeLa cells were grown to
con£uence on a 6 well plate for 4^6 h. And then, the culture medium
was replaced with 1 ml of fresh solution without a fetal bovine serum.
After HeLa cells were treated with various concentrations of Tat^
SOD for 1 h, the cells were treated with trypsin^EDTA and washed
with phosphate-bu¡ered saline (PBS). The cells were harvested for the
preparation of cell extracts to perform a SOD enzyme assay and
Western blot analysis. The dismutation activity of SOD in cell extracts
was measured by monitoring the inhibition of ferricytochrome c re-
duction by the xanthine/xanthine oxidase reaction described pre-
viously [22]. For Western blotting, proteins in cell extracts were
separated on a 15% sodium dodecyl sulfate^polyacrylamide gel elec-
trophoresis (SDS^PAGE) and the proteins were transferred onto a
nitrocellulose membrane. The membranes were incubated with 5%
BSA in PBS, and then with a monoclonal anti-human Cu,Zn-SOD
antibody (hSOD mAb-1.4) for 1 h at room temperature. After they
were washed, the membranes were then incubated with an alkaline
phosphatase-conjugated goat anti-mouse IgG antibody (Sigma, di-
luted 1:5000) for 1 h at room temperature. Immunoreactive bands
were visualized with the alkaline phosphatase conjugate substrate
kit (Bio-Rad) according to the manufacturer’s protocol. The intra-
cellular stability of transduced Tat^SOD fusion protein was estimated
as follows: After HeLa cells were treated with 2 WM denatured Tat^
SOD for 1 h, the cells were washed and changed with a fresh culture
medium to remove Tat^SOD that was not transduced. And then, cells
were further incubated for 3, 6, 12, 24 and 48 h, followed by prepa-
rations of cell extracts for a SOD enzyme assay and Western blot
analysis.
2.4. E¡ect of transduced Tat^SOD on cell viability of paraquat-treated
HeLa cells
The biological activity of transduced Tat^SOD was assessed by the
cell viability of HeLa cells treated with paraquat (methyl viologen),
which is well known as an intracellular superoxide anion generator [2].
Cells were plated into 6 well trays at 70% con£uence, and they were
allowed to attach cells per well. After the cells were treated with
0.1V2 WM denatured Tat^SOD and control SOD for 1 h, respec-
tively, then the 5 mM paraquat was added to the culture medium
for 12 h. Cell viability was estimated by with a colorimetric assay
using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide).
3. Results and discussion
Cu,Zn-SOD is one of the cell’s primary defenses against
oxygen-derived free radicals, and it is vital for maintaining a
healthy balance between oxidants and antioxidants. Recently,
it has been reported that the point mutations of Cu,Zn-SOD
have been linked to familial amyotrophic lateral sclerosis
Fig. 1. Construction of Tat^SOD expression vector system (pTat^
SOD) based on the vector pET15b (A). The synthetic Tat oligomer
was cloned into the NdeI, XhoI sites, and 486 bp of human Cu,Zn-
SOD cDNA was cloned into XhoI, BamHI sites of pET15b. The ex-
pression vector is under the control of the T7 promoter and lacO-
operator. The expression is induced by the addition of IPTG. Dia-
gram of expressed Tat^SOD and control SOD fusion proteins (B).
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(FALS) [23]. Transgenic mice that express a mutant Cu,Zn-
SOD have been shown to develop amyotrophic lateral sclero-
sis (ALS) symptoms [24]. In an e¡ort to replenish the Cu,Zn-
SOD activity in the patients like FALS, we are describing a
genetic approach of the Tat^SOD fusion protein into the cells.
To develop an expression system to overexpress and simply
purify the cell-permeable SOD protein, we constructed the
Tat^SOD expression vector (pTat^SOD), which contains con-
secutive cDNA sequences encoding the human Cu,Zn-SOD,
Tat-protein transduction domain (Tat49ÿ57) and six histidine
residues at the amino-terminus (Fig. 1A). We also constructed
the SOD-expression vector (pSOD) to produce control SOD
protein without an HIV-1 Tat-protein transduction domain
(Fig. 1B).
Transfected bacterial cells induced with IPTG were lysed at
4‡C in a PBS bu¡er. The crude cell extracts obtained from E.
coli were used for electrophoresis in 15% SDS^PAGE. Fig. 2A
shows the protein bands visualized by staining with Coomas-
sie brilliant blue. The bands marked by arrows in lane 2 (Tat^
SOD) and lane 3 (SOD), in comparison with that of the lane 1
(pET15b vector) alone, indicate that the protein was expressed
at a very high level with a major component of the total
soluble proteins in the cells. Recombinant proteins were puri-
¢ed homogeneously from cell lysates by Ni2-nitrilotriacetic
acid Sepharose a⁄nity chromatography under denaturing and
native conditions, respectively (Fig. 2B). The yields of fusion
proteins puri¢ed were approximately 20 mg/l culture. The
recombinant Tat^SOD and SOD proteins have an estimated
molecular mass of approximately 18 and 17 kDa, respectively.
However, it was detected that recombinant fusion proteins
migrate to bands with a higher molecular weight than those
of the expected sizes on the SDS^PAGE (as shown in Fig.
2B), which is consistent with the previous reports [25,26]. The
puri¢ed products were further con¢rmed by Western blot
analysis using a monoclonal antibody to a human Cu,Zn-
SOD (Fig. 2C). Tat^SOD and SOD were detected at the cor-
responding bands in Fig. 2B.
To evaluate the transduction ability of Tat^SOD, 1 WM of
Tat^SOD proteins puri¢ed under denaturing and native con-
ditions were added to the culture media of HeLa cells for 1 h,
and they were analyzed by the Western blot technique. As
shown in Fig. 2D, denatured Tat^SOD was successfully deliv-
ered into the cells, whereas native Tat^SOD and the control
SOD were not delivered into the cells. These results indicate
that protein unfolding is required for e⁄cient transduction of
Tat^SOD into HeLa cells. Although the exact mechanisms for
protein transduction are still entirely unclear, Derossi et al.
demonstrated that the Antennapedia homeodomain (Antp),
another protein transduction domain from Drosophila, was
internalized by cells in a receptor- and transporter-independ-
ent mechanism [15].
As shown in Fig. 3, we then analyzed the transduction of
denatured Tat^SOD fusion protein into the cells. Denatured
Tat^SOD proteins were added to the culture media of HeLa
Fig. 2. Expression and puri¢cation of Tat^SOD in E. coli. Protein
extracts of cells (A) and puri¢ed fusion proteins (B) were analyzed
by 15% SDS^PAGE gel and subjected to Western blot analysis with
a monoclonal antibody to human Cu,Zn-SOD (C). Lanes in A are
as follows: extracts of bacteria containing expression vector pET
(lane 1), pTat^SOD (lane 2), and pSOD (lane 3). Lanes in B and C
are as follows: lane 1, Tat^SOD; lane 2, SOD. Transduction of
Tat^SOD fusion proteins into cultured HeLa cells (D). 1 WM of
Tat^SOD and control SOD were added to the culture media for 1 h
and analyzed by Western blot analysis. Lanes are as follows: lane
1, denatured Tat^SOD; lane 2, denatured SOD; lane 3, native Tat^
SOD; lane 4, native SOD.
Fig. 3. Time- and dose-dependent transduction of Tat^SOD into
cultured HeLa cells. 1 WM of denatured Tat^SOD and control SOD
were added to the culture media for 5 min^1 h (A), 0.25^2 WM of
denatured Tat^SOD and control SOD were added to the culture
media for 1 h (B). Transduced Tat^SOD into the cells was analyzed
by Western blotting.
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cells at 1 WM concentration for various times, and the level of
transduced proteins was analyzed by Western blotting. The
intracellular concentration of transduced Tat^SOD into cul-
tured cells was detected after 5 min and gradually increased by
1 h (Fig. 3A). This time-dependent manner of transduction
indicated that Tat^SOD was rapidly transduced into cells. It
was reported that Tat^L-galactosidase fusion protein was
transduced rapidly into HepG2 cells, reaching near maximum
intracellular concentrations in less than 15 min [17]. This little
di¡erence in time course may derive from the properties of
transduced Tat fusion protein, such as the unfolding degree,
polarity, and the molecular shape of the protein.
The dose-dependency of the transduction of denatured Tat^
SOD fusion proteins was further analyzed. Various concen-
trations of denatured Tat^SOD proteins were added to the
culture media of HeLa cells for 1 h, and the levels of trans-
duced proteins were measured by Western blotting. As shown
in Fig. 3B, the levels of transduced proteins in the cultured
HeLa cells were increased concomitantly with the amounts of
fusion proteins treated in media.
The restoration of authentic properties of transduced pro-
tein in the cells is a key point in application of the protein-
transduction technology to the therapeutic use. Therefore, we
determined the dismutation activities of SOD in the cells
treated with denatured Tat^SOD. As shown in Fig. 4, the
enzyme activities of Cu,Zn-SOD in the cultured HeLa cells
were increased in a time- and dose-dependent manner. The
enzyme-speci¢c activities were increased about 2^5-fold by
treatment with various concentrations of denatured Tat^
SOD, but they were not in cells treated with native Tat^
SOD. These results implicate that denatured Tat^SOD in
HeLa cells may be correctly refolded by the mechanism of
Fig. 4. The speci¢c activities of SOD in cultured HeLa cells treated
with Tat^SOD. 1 WM of denatured Tat^SOD was added to the cul-
ture media for 5 min^1 h (A), 0.25^2 WM of denatured Tat^SOD
was added to the culture media for 1 h (B). Each bar represents the
mean þ S.E.M. obtained from four experiments.
Fig. 5. The stability of transduced Tat^SOD into cultured HeLa
cells. Cells pretreated with 2 WM Tat^SOD were incubated for 3^48
h. Transduced Tat^SOD was identi¢ed by Western blot analysis (A)
and by an enzyme assay (B), respectively. Each bar in B represents
the mean þ S.E.M. obtained from four experiments.
Fig. 6. E¡ect of transduced Tat^SOD on cell viability of HeLa cells
treated with paraquat (Pq, 5 mM) was added to the HeLa cells pre-
treated with 0.1^2 WM Tat^SOD, and control SOD for 1 h, respec-
tively. Cell-viability was estimated by with a colorimetric assay us-
ing MTT. Each bar represents the mean þ S.E.M. obtained from
¢ve experiments. Asterisks and crosses denote statistical signi¢cance
at P6 0.05 and P6 0.01, respectively. The statistical analysis was
evaluated by Student’s t-test.
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molecular chaperone or by a spontaneous process. However,
intracellular refolding mechanisms for transduced proteins
wait to be elucidated in the future.
The intracellular stability and enzymatic activity of trans-
duced Tat^SOD into HeLa cells was shown in Fig. 5. The
apparent degradation of transduced Tat^SOD was observed
as a function of incubation time. However, signi¢cant levels of
transduced protein and enzyme activity persisted in HeLa cells
until 24 h. To determine whether transduced Tat^SOD can
play its biological role in the cells, we have tested the e¡ect of
transduced Tat^SOD on cell-viability under oxidative stress.
After the cells were exposed to 5 mM paraquat without Tat^
SOD, only 36% of the HeLa cells were viable; the viability
was signi¢cantly increased when Tat^SOD was pretreated in a
dose-dependent manner (Fig. 6). The cell-viability of HeLa
cells pretreated with 0.25V2 WM Tat^SOD was increased
by approximately 40^80% as compared with that of the con-
trol. These results indicate that transduction of Tat^SOD was
de¢nitely e¡ective against superoxide anion induced by para-
quat in HeLa cells.
Taken together, the present experimental results demon-
strate that exogenous human Cu,Zn-SOD fused with Tat pro-
tein can be directly transduced into the cells, and the delivered
enzymatically active Tat^SOD exhibits a cellular protective
function against oxidative stress. Therefore, this transduction
may allow the therapeutic delivery of Cu,Zn-SOD for the
various disorders related to this antioxidant enzyme.
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